Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Biogen Inc. completed its acquisition of Apellis Pharmaceuticals, which is now a wholly owned subsidiary. Biogen’s tender offer valued Apellis at $41.00 in cash per share plus one contingent value right (CVR) per share, with each CVR allowing up to an additional $4.00 in cash if specified sales milestones are met. Approximately 105,687,831 Apellis shares, or about 82.4% of outstanding shares, were tendered before closing. The total cash consideration for the offer and merger is about $5.3 billion, funded with cash and a new $2 billion unsecured term loan split into two $1 billion tranches. Apellis’ key products, EMPAVELI and SYFOVRE, generated $689 million in 2025 net product revenue, and Biogen expects the deal to be accretive to its non‑GAAP diluted EPS in 2027 and to support longer‑term earnings growth.
Biogen's wholly owned purchaser accepted for payment 105,687,831 Shares tendered in the offer for Apellis, representing approximately 82.4% of Shares outstanding immediately prior to the offer's expiration. The offer provided $41.00 per Share in cash plus one contingent value right per Share for up to $4.00 in additional cash upon specified milestones. All conditions to closing were satisfied or waived and, pursuant to the Merger Agreement and Section 251(h) of the DGCL, Purchaser will merge with and into Apellis and the merger will be consummated on May 14, 2026. At the Effective Time, each outstanding Share (subject to limited exceptions) will be converted into the right to receive the Merger Consideration, the Shares will be delisted from Nasdaq, and Apellis will become a wholly owned subsidiary of Biogen.
Biogen's wholly owned purchaser accepted for payment 105,687,831 Shares tendered in the offer for Apellis, representing approximately 82.4% of Shares outstanding immediately prior to the offer's expiration. The offer provided $41.00 per Share in cash plus one contingent value right per Share for up to $4.00 in additional cash upon specified milestones. All conditions to closing were satisfied or waived and, pursuant to the Merger Agreement and Section 251(h) of the DGCL, Purchaser will merge with and into Apellis and the merger will be consummated on May 14, 2026. At the Effective Time, each outstanding Share (subject to limited exceptions) will be converted into the right to receive the Merger Consideration, the Shares will be delisted from Nasdaq, and Apellis will become a wholly owned subsidiary of Biogen.
Biogen's subsidiary filed Amendment No. 2 to the Schedule TO to update the tender offer terms for all outstanding Apellis Pharmaceuticals common shares. The offer provides $41.00 per share in cash plus one contractual, non-transferable contingent value right (CVR) per share for up to $4.00 aggregate upon milestone achievement. This amendment states the Regulatory Condition was satisfied when the waiting period under the HSR Act expired at 11:59 p.m. Eastern Time on May 11, 2026, clearing a required antitrust review step. Signatures are dated May 12, 2026.
Biogen's subsidiary filed Amendment No. 2 to the Schedule TO to update the tender offer terms for all outstanding Apellis Pharmaceuticals common shares. The offer provides $41.00 per share in cash plus one contractual, non-transferable contingent value right (CVR) per share for up to $4.00 aggregate upon milestone achievement. This amendment states the Regulatory Condition was satisfied when the waiting period under the HSR Act expired at 11:59 p.m. Eastern Time on May 11, 2026, clearing a required antitrust review step. Signatures are dated May 12, 2026.
BIOGEN INC ownership filing: FMR LLC reports beneficial ownership of 12,807,541.50 shares of Common Stock, representing 8.7% of the class as of 03/31/2026. The filing is an amendment (Schedule 13G/A) naming Abigail P. Johnson in a related disclosure and references an exhibit identifying the acquiring subsidiary and a power of attorney.
BIOGEN INC. Head of Corporate Development Adam Keeney reported routine equity compensation transactions involving the company’s common stock. On May 1, 2026, 939 restricted stock units were exercised into 939 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations, 455 shares of common stock were disposed of at a price of $187.06 per share as a tax-withholding transaction, not an open-market sale. Following these transactions, Keeney directly owned 6,365 shares of Biogen common stock. The restricted stock units that were exercised were part of an award that vests in three equal yearly installments beginning on the first anniversary of the May 1, 2023 grant date.
Biogen Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 10,989,562 shares of Biogen common stock, representing 7.48% of the class. The filing shows Vanguard has sole voting power for 1,452,145 shares and sole dispositive power for 10,989,562 shares.
The Schedule 13G statement describes holdings across Vanguard business units and notes the reported interests include shares held for Vanguard funds and other managed accounts.
Biogen Inc. reported modestly higher quarterly revenue and stronger profits while outlining a sizable acquisition. For the three months ended March 31, 2026, revenue rose to $2.48 billion from $2.43 billion a year earlier, driven by multiple sclerosis, rare disease and anti-CD20 program revenue.
Net income attributable to Biogen increased to $319.5 million, up from $240.5 million, with diluted EPS improving to $2.15 from $1.64. Operating cash flow strengthened to $645.5 million, supporting a cash and cash equivalents balance of $3.38 billion and total assets of $29.48 billion.
Biogen also agreed to acquire Apellis Pharmaceuticals for $41.00 per share in cash, valuing the deal at about $5.6 billion, plus a contingent value right of up to $4.00 per share tied to SYFOVRE sales. The company plans to fund the purchase with roughly $3.6 billion of existing cash and marketable securities and about $2.0 billion in bank loans, aiming to add two approved immunology and rare disease products to its portfolio.
Biogen Inc. reported first quarter 2026 revenue of $2.48 billion, up 2% year-over-year, with GAAP diluted EPS of $2.15 (up 31%) and Non-GAAP diluted EPS of $3.57 (up 18%). Growth products collectively grew 12% year-over-year, led by LEQEMBI in‑market sales of $168 million, SKYCLARYS at $151 million, ZURZUVAE at $55 million, VUMERITY at $179 million, SPINRAZA at $374 million, and QALSODY at $33 million.
Biogen highlighted new positive data from late-stage programs, including litifilimab in cutaneous lupus and additional salanersen data in SMA, as well as strong LEQEMBI persistence and U.S. approval of the SPINRAZA High Dose Regimen. The company announced a proposed acquisition of Apellis Pharmaceuticals, expected to be accretive in 2027 and to materially increase Biogen’s Non-GAAP diluted EPS compounded annual growth rate through the end of the decade. Biogen also signed an agreement with TJ Biopharma for exclusive felzartamab rights in Greater China.
For full year 2026, Biogen now expects Non-GAAP diluted EPS between $14.25 and $15.25, excluding any Apellis impact, and anticipates total revenue will decline by a mid-single digit percentage versus 2025. The EPS outlook includes about $1.00 of acquired IPR&D charges tied to ongoing business development. Q1 2026 free cash flow was $594.3 million, and cash and cash equivalents were $3.38 billion as of March 31, 2026.